BIDS Grand Rounds

Yong Chen PhD, professor of biostatistics at the University of Pennsylvania, will introduce XYZ, a unified framework that advances clinical evidence generation by jointly modeling the treatment (X), outcome (Y), and population (Z) dimensions. This framework is built to support AI-driven drug repurposing, outcome profiling, and multi-dimensional optimization of eligibility criteria using real-world data. By integrating lossless federated target trial emulation for drug discovery, negative control–based debiasing for robust outcome inference, and AI-guided simulation to evaluate alternative inclusion criteria across real-world populations. XYZ enables principled and scalable evidence generation. Applications in repurposing GLP-1 RA, drug identification for AD/ADRD, and trial design for advanced non-small cell lung cancer (NSCLC) illustrate how XYZ enhances generalizability, supports regulatory alignment, and ensures reliable insights generated from distributed research networks.